This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

LUNGevity Foundation Announces Additions To Board Of Directors

Contributing Valuable Experience to Support LUNGevity's Strategic Growth

WASHINGTON, April 2, 2013 /PRNewswire-USNewswire/ -- LUNGevity Foundation, the nation's largest lung cancer-focused organization, is pleased to announce additions to its Board of Directors to guide and assist its continued growth and expansion.

Peter Babej is Global Co-Head of the Financial Institutions Group at Citi. Previously, Peter served as Co-Head of Financial Institutions – Americas at Deutsche Bank and as a Managing Director at Lazard. Over the course of his career, Peter has advised many leading companies across the financial and public sectors worldwide with respect to both mergers and acquisitions and financing.

Grace Bender comes to LUNGevity with extensive experience in public relations, government relations, management, and community volunteer work. She has been active in many non-profit organizations, both as a board and committee member, contributing to program development, fundraising, financial management, and special events. Her company infinisity, inc . produces healthcare aids such as mymedmanager ™, a personal healthcare and medication organizer.

Dr. Pierre Massion is Chairman of LUNGevity Foundation's Scientific Advisory Board and Director of the Thoracic Program at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee.  Dr. Massion is pursuing innovative methods to deepen the knowledge of tumorigenesis as well as developing molecular strategies for the early detection of lung cancer.

Chris Olivier is an entrepreneur with extensive consumer marketing and general management experience, working in operating roles in both private equity and non-profit arenas.  Currently, Chris is a principal in Craft Catalyst, a beverage brand accelerator helping emerging brands manage their growth.   Chris served as an active board member of Take Aim At Cancer, a non-profit focused on raising funds and awareness for targeted cancer therapy. LUNGevity is delighted that Take Aim at Cancer has joined with LUNGevity to help accelerate the funding of as much impactful research as possible. 

"I am honored and thrilled that Grace, Chris, Peter, and Pierre have agreed to serve on our board," said Andrea Stern Ferris, President and Chairman of the Board of LUNGevity. "Each contributes valuable experience and the type of vision we rely upon as we continue to grow LUNGevity's impact on behalf of our lung cancer community."

About LUNGevity Foundation

The mission of LUNGevity Foundation is to have a meaningful impact on improving lung cancer survival rates, ensure a higher quality of life for lung cancer patients and provide a community for those impacted by lung cancer. We do so by supporting critical research into the early detection and successful treatment of lung cancer, as well as by providing information, resources and a support community to patients and caregivers.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs